Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients

OBJECTIVE: Osimertinib is the standard targeted strategy for lung adenocarcinoma patients harboring epidermal growth factor receptor (EGFR)-activating mutation who have achieved acquired mutation T790M beyond progression of first-line EGFR-tyrosine kinase inhibitor (TKI). In a real world setting, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ziyi, Hao, Xuezhi, Wang, Qi, Wang, Jing, Yang, Ke, Wang, Shouzheng, Teng, Fei, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898015/
https://www.ncbi.nlm.nih.gov/pubmed/35256860
http://dx.doi.org/10.2147/CMAR.S346173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898015/
https://www.ncbi.nlm.nih.gov/pubmed/35256860
http://dx.doi.org/10.2147/CMAR.S346173

Ejemplares similares